Bimzelx (bimekizumab-bkzx) — Point32Health
Ankylosing spondylitis
Preferred products
- Cimzia
- Enbrel
- Humira
- Rinvoq
- Simponi
- Taltz
- Xeljanz
Initial criteria
- Documented diagnosis of ankylosing spondylitis
- Patient age ≥ 18 years
- Prescribed by or in consultation with a rheumatologist
- Documentation of one (1) of the following: a. Both of the following: i. One (1) of the following: 1. Inadequate response or adverse reaction to one (1), or contraindication to all prescription strength non-steroidal anti-inflammatory drug (e.g., celecoxib, diclofenac, ibuprofen, naproxen, meloxicam) OR 2. Previous treatment with a biologic agent indicated for the requested use AND ii. Trial and failure with two (2), or contraindication to all of the following: Cimzia, Enbrel, Humira, Rinvoq, Simponi, Taltz, Xeljanz OR b. The patient is new to the plan and stable on Bimzelx and the prescribing physician has documented that changing to a preferred product would result in adverse clinical outcomes